This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
January 7, 2013 /PRNewswire/ --
PremierEquityReports.com provides investors with quality research and analysis on U.S. equities on the move and today issues a report on: Medi Swipe, Inc. (OTCBB: MWIP), New Western Energy, Inc. (OTCBB: NWTR), Titan Pharmaceuticals, Inc. (OTCBB: TTNP), and Advanced Cell Technology, Inc. (OTCBB: ACTC).
Medi Swipe, Inc. (OTCBB: MWIP) has recently announced a new corporate headquarters in
Birmingham, Michigan. The Company made the decision to move from
South Florida based on recent and favorable state legislation regarding medical marijuana and dispensary laws. Medi Swipe, Inc. hit a new all-time high of
January 4, 2013. Medi Swipe, Inc. has gained nearly 135% so far in the month of January.
Read the entire press release issued by Medi Swipe, Inc. (OTCBB: MWIP) here:
New Western Energy Corp. (OTCBB: NWTR) has recently completed the acquisition of 8 property leases totaling 1,520 acres and 106 oil wells in Roger County,
Oklahoma, from Pioneer Oil Development LLC. New Western Energy intends to provide the development funds necessary to bring in to production the existing wells, as well as the drilling of additional wells upon completion of the work overs. Within the acquired leases is 950 contiguous acres of which a full 640 acre section has open drilling opportunities of multiple proven oil and gas formations.
President and CEO,
Javan Khazali, stated, "We are continuing to execute on our strategy of aggressively acquiring performing assets that are underdeveloped and will drive our growth in production." New Western Energy hit a new all-time high of
January 3, 2013.
Read the entire press release issued by New Western Energy Corp. (OTCBB: NWTR) here:
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) recently announced that the New Drug Application (NDA) for Probuphine® has been accepted for review and granted Priority Review designation by the U.S. Food and Drug Administration (FDA). Probuphine® is a novel, sub dermal implant and the first long-acting product designed to deliver six months of the drug buprenorphine hydrochloride following a single treatment. Titan Pharmaceuticals submitted the NDA for the maintenance treatment of opioid dependence in adult patients in
October 2012 under Section 505(b)(2) of the Food, Drug and Cosmetic Act and referenced the approved sublingual tablet formulations of buprenorphine.
Titan Pharmaceuticals, Inc. has gained nearly 31% so far in the month of January.